drugset
drugset / Trial / NCT05259085

Study of ALXN2050 in Participants With Hepatic Impairment

NCT05259085 ↗

Phase 1 Terminated 26 enrolled Alexion Pharmaceuticals, Inc.
NaSingle-groupOpen-labelBasic science

Summary

This study will investigate the impact of impaired hepatic function (IHF) on the plasma pharmacokinetics of ALXN2050 in order to provide dosing recommendations for future indications in individuals with varying degrees of IHF.

Timeline

Start
2022-04-07
Primary completion
2024-08-12
Completion
2024-08-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Vemircopan Small molecule 120 mg Oral

Indications

No indication recorded.